{"id":"https://openalex.org/W2141165482","doi":"https://doi.org/10.1002/jps.22225","title":"Risk Assessment and Physicochemical Characterization of a Metastable Dihydrate API Phase for Intravenous Formulation Development","display_name":"Risk Assessment and Physicochemical Characterization of a Metastable Dihydrate API Phase for Intravenous Formulation Development","publication_year":2010,"publication_date":"2010-05-27","ids":{"openalex":"https://openalex.org/W2141165482","doi":"https://doi.org/10.1002/jps.22225","mag":"2141165482","pmid":"https://pubmed.ncbi.nlm.nih.gov/20821397"},"language":"en","primary_location":{"id":"doi:10.1002/jps.22225","doi":"https://doi.org/10.1002/jps.22225","is_oa":false,"landing_page_url":"https://doi.org/10.1002/jps.22225","pdf_url":null,"source":{"id":"https://openalex.org/S130661733","display_name":"Journal of Pharmaceutical Sciences","issn_l":"0022-3549","issn":["0022-3549","1520-6017"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmaceutical Sciences","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023908078","display_name":"Christopher J. Mortko","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Christopher J. Mortko","raw_affiliation_strings":["Basic Pharmaceutical Sciences, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, USA. christopher_mortko@merck.com","Basic Pharmaceutical Sciences, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Basic Pharmaceutical Sciences, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, USA. christopher_mortko@merck.com","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"Basic Pharmaceutical Sciences, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000192073","display_name":"Agam R. Sheth","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Agam R. Sheth","raw_affiliation_strings":["Pharmaceutical Research & Development, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research & Development, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047982691","display_name":"Narayan Variankaval","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Narayan Variankaval","raw_affiliation_strings":["Pharmaceutical Research & Development, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research & Development, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Li Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Li Li","raw_affiliation_strings":["Pharmaceutical Analytical Chemistry, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Analytical Chemistry, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5075155514","display_name":"Brian T. Farrer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian T. Farrer","raw_affiliation_strings":["Basic Pharmaceutical Sciences, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Basic Pharmaceutical Sciences, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065","institution_ids":["https://openalex.org/I1285764155"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5023908078"],"corresponding_institution_ids":["https://openalex.org/I1285764155"],"apc_list":{"value":3620,"currency":"USD","value_usd":3620},"apc_paid":null,"fwci":0.3138,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.58446166,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"99","issue":"12","first_page":"4973","last_page":"4981"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11881","display_name":"Crystallization and Solubility Studies","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2505","display_name":"Materials Chemistry"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T11881","display_name":"Crystallization and Solubility Studies","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2505","display_name":"Materials Chemistry"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.0071000000461936,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11124","display_name":"Protein purification and stability","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastable-polymorphs","display_name":"metastable polymorphs","score":0.7129999995231628},{"id":"https://openalex.org/keywords/beta-lactamase-inhibitors","display_name":"beta-lactamase inhibitors","score":0.8159999847412109},{"id":"https://openalex.org/keywords/intravenous-formulation","display_name":"intravenous formulation","score":0.8980000019073486},{"id":"https://openalex.org/keywords/amorphous-solids","display_name":"amorphous materials","score":0.6660000085830688},{"id":"https://openalex.org/keywords/crystal-polymorphism","display_name":"crystal polymorphism","score":0.7049999833106995},{"id":"https://openalex.org/keywords/physicochemical-characterization","display_name":"physicochemical characterization","score":0.7760000228881836},{"id":"https://openalex.org/keywords/risk-assessment","display_name":"risk assessment","score":0.7839999794960022},{"id":"https://openalex.org/keywords/preformulation","display_name":"preformulation","score":0.7789999842643738}],"concepts":[{"id":"https://openalex.org/C155574463","wikidata":"https://www.wikidata.org/wiki/Q170731","display_name":"Solubility","level":2,"score":0.7218791246414185},{"id":"https://openalex.org/C88380143","wikidata":"https://www.wikidata.org/wiki/Q416674","display_name":"Dissolution","level":2,"score":0.658021867275238},{"id":"https://openalex.org/C56052488","wikidata":"https://www.wikidata.org/wiki/Q103382","display_name":"Amorphous solid","level":2,"score":0.6052231788635254},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.598533570766449},{"id":"https://openalex.org/C184651966","wikidata":"https://www.wikidata.org/wiki/Q906356","display_name":"Aqueous solution","level":2,"score":0.49356091022491455},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.46482259035110474},{"id":"https://openalex.org/C2777854178","wikidata":"https://www.wikidata.org/wiki/Q150668","display_name":"Heptane","level":2,"score":0.45319804549217224},{"id":"https://openalex.org/C89464430","wikidata":"https://www.wikidata.org/wiki/Q849516","display_name":"Metastability","level":2,"score":0.4510207176208496},{"id":"https://openalex.org/C85906118","wikidata":"https://www.wikidata.org/wiki/Q186693","display_name":"Phase diagram","level":3,"score":0.4360122084617615},{"id":"https://openalex.org/C43617362","wikidata":"https://www.wikidata.org/wiki/Q170050","display_name":"Chromatography","level":1,"score":0.39358943700790405},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.2905545234680176}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001618","descriptor_name":"beta-Lactamases","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D002626","descriptor_name":"Chemistry, Pharmaceutical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D003460","descriptor_name":"Crystallization","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004355","descriptor_name":"Drug Stability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004364","descriptor_name":"Pharmaceutical Preparations","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004364","descriptor_name":"Pharmaceutical Preparations","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D006860","descriptor_name":"Hydrogen Bonding","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007275","descriptor_name":"Injections, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D008970","descriptor_name":"Molecular Weight","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010316","descriptor_name":"Particle Size","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012995","descriptor_name":"Solubility","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D014867","descriptor_name":"Water","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019086","descriptor_name":"Bridged Bicyclo Compounds, Heterocyclic","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019086","descriptor_name":"Bridged Bicyclo Compounds, Heterocyclic","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D055598","descriptor_name":"Chemical Phenomena","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065093","descriptor_name":"beta-Lactamase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/jps.22225","doi":"https://doi.org/10.1002/jps.22225","is_oa":false,"landing_page_url":"https://doi.org/10.1002/jps.22225","pdf_url":null,"source":{"id":"https://openalex.org/S130661733","display_name":"Journal of Pharmaceutical Sciences","issn_l":"0022-3549","issn":["0022-3549","1520-6017"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmaceutical Sciences","raw_type":"journal-article"},{"id":"pmid:20821397","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20821397","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of pharmaceutical sciences","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.5683000087738037,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W169016419","https://openalex.org/W279088417","https://openalex.org/W625323494","https://openalex.org/W651534235","https://openalex.org/W1544389379","https://openalex.org/W1972653548","https://openalex.org/W1991957603","https://openalex.org/W2039306788","https://openalex.org/W2039442233","https://openalex.org/W2051671467","https://openalex.org/W2051737824","https://openalex.org/W2062586144","https://openalex.org/W2067791635","https://openalex.org/W2117669255","https://openalex.org/W2117957892","https://openalex.org/W2148930935","https://openalex.org/W2937357360","https://openalex.org/W4230831096","https://openalex.org/W4247665233","https://openalex.org/W4285719527","https://openalex.org/W6726627451"],"related_works":["https://openalex.org/W7101471469","https://openalex.org/W2570074941","https://openalex.org/W4411216973","https://openalex.org/W2046179634","https://openalex.org/W2327682989","https://openalex.org/W2952434646","https://openalex.org/W4291465466","https://openalex.org/W2748869454","https://openalex.org/W2328298168","https://openalex.org/W4411184741"],"abstract_inverted_index":null,"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}